Clinical & Experimental Immunology · 2008 · 25 citations · 43 references
Veterinary MedicineImmunologyPathologyImmunopathologyInflammationParasitic Skin DiseaseCytokine BiologyCytokine SignalingCytokine-mediated PathologyImmunopathology Of Parasitic DiseaseInflammatory BiomarkersInflammatory MediatorsCytokine Expression RegulationCytokine Gene Expression RegulationCytokine Receptor ExpressionImmunopathology Of LeishmaniasisLeishmaniasis PathogenesisLeishmaniasis PathologyMatrix MetalloproteinasesPost-kala-azar Dermal Leishmaniasis
Semi-quantitative RT-PCR was exploited to analyse the intralesional cytokine gene expression in 14 post-kala-azar dermal leishmaniasis (PKDL) and 10 kala-azar (KA) patients. The data provided evidence for both inflammatory and non-inflammatory responses, as reflected by elevated tumour necrosis factor (TNF)-alpha and interleukin (IL)-10 in PKDL lesions compared with normal skin tissue (n = 6). The ratio of TNF-alpha : IL-10 message was 2.66 in PKDL cases, substantially higher than in KA (1.18). Investigation of TNF-alpha receptors (TNFR1 and TNFR2) revealed a significant down-regulation of TNFR1 transcript in both PKDL and KA compared with control. In the presence of elevated levels of TNF-alpha transcript, interference with type 1 effector activity in PKDL may be due to minimal expression of the TNFR1 gene. Investigation of matrix metalloproteinases, known to be induced by TNF-alpha, and the tissue inhibitors of matrix metalloproteinases (TIMPs), provided evidence for the roles of TIMP-1 and TIMP-3 in the pathogenesis of PKDL.
43
Activation mechanisms of matrix metalloproteinases.
Hideaki Nagase · PubMed · 1997 · 1.1K citations
Matrix metalloproteinases in immunity
Edward J. Goetzl, Michael J. Banda, David Leppert · The Journal of Immunology · 1996 · 555 citations · Full text
F Y Liew, Y Li, S Millott · The Journal of Immunology · 1990 · 520 citations · Full text
Tumor necrosis factors: developments during the last decade.
B B Aggarwal, Kasthuri Natarajan · PubMed · 1996 · 469 citations
Life Sciences, Immunology, Oncology +14